** PLEASE NOTE THAT THIS STUDY IS NO LONGER RECRUITING PATIENTS **
To establish a non-invasive method for detecting and quantifying circulating osteosarcoma tumour cells in dogs with diagnosed osteosarcoma undergoing treatment by examining peripheral blood samples using flow cytometry.
Osteosarcoma is a highly malignant cancer that rapidly spreads to other body locations, such as the lungs and other bones resulting in patient death.
Despite advanced imaging, our ability to identify and stage early metastatic disease remains poor. Improved methods for early detection of early metastasis could allow for accurate monitoring of disease progression, evaluating response to treatment and improved estimation of overall prognosis. Recent research efforts in humans have been focused on the development of sensitive, accurate, minimally-invasive, and cost-effective tests that allow detection of circulating tumour cells (CTCs) in peripheral blood. Circulating tumour cells shed from primary tumour lesions have the potential to generate distant metastases. CTCs are considered rare in peripheral circulation, but detection and measurement of CTCs in human cancer patients has been shown to correlate with disease malignancy and stage.
Measurement of CTCs is performed on peripheral blood, collected in a routine and non-invasive manner. 1-3 ml of blood will be collected.
Flow cytometry has been established as a method for identifying CTCs in human patients with various other forms of cancer. A protocol has yet to be established in veterinary or human patients specifically for osteosarcoma.
For further information please contact:
Dr. Vicky Sabine (PhD), Clinical Research Coordinator
Email address: email@example.com
Work cell #: 226-218-0338